Radiometer

Etiometry Unveils 2024 Priorities and Celebrates Milestones: Clinical Outcomes Data Show Significant Reductions in Length of Stay (LOS)

Retrieved on: 
Tuesday, January 30, 2024
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, Carbon, Partnership, Abstract, Cardiology, ICU, Attention, EHR, IDO2, Hypercapnia, Hospice and palliative medicine, Research, Nursing care plan, Hospital, NICU, Analytics, Patient, Safety, Data science, FDA, SOC, Automation, QIA, Radiometer, Carbon dioxide, Algorithm, Purchasing, Length of stay, Quality, System, Pharmaceutical industry

A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.

Key Points: 
  • A multicenter randomized clinical trial showed a reduction in time patients were on vasoactive medication by 18%.
  • This was the first study to explore the use of algorithms in the safe de-escalation of care.
  • "The clinical outcomes data tell a compelling story of how Etiometry's platform is reshaping the landscape of critical care.
  • As the evidence highlighting the clinical efficacy of the Etiometry platform continues to grow, so does the attention from industry stakeholders.

After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion

Retrieved on: 
Tuesday, January 31, 2023
Technology, FDA, Clinical Trials, Health Technology, Software, Networks, Health, Data Management, Artificial Intelligence, Heel, Operating, Radiometer, Hospice and palliative medicine, Attention, Hospital, IDO2, Nursing care plan, Data science, Safety, Patient safety, Patient, HLA, Geography, Pediatrics, Research, Acidosis, Risk, Intensive care medicine, Partnership, Growth, CE marking, ACD, Metabolic acidosis, Pharmaceutical industry, Nursing

On the heels of record growth in 2021, Etiometry harnessed the momentum moving into 2022, more than doubling sales over 2021, and also initiated its first adult hospital installations.

Key Points: 
  • On the heels of record growth in 2021, Etiometry harnessed the momentum moving into 2022, more than doubling sales over 2021, and also initiated its first adult hospital installations.
  • On the regulatory front, Etiometry announced this month its eighth FDA clearance ; the IDO2 IndexTM is now cleared for adult use.
  • “Our regulatory success uniquely positions Etiometry for further developments in 2023 that will result in enhanced offerings benefiting patients and the care teams treating them,” said Shane Cooke, CEO of Etiometry.
  • Capping off the year, Frost & Sullivan presented Etiometry with its Enabling Technology Leadership Award for critical care decision making.

Abbott, Roche and Danaher Lead $54 Billion U.S. In Vitro Diagnostic (IVD) Market: Kalorama Information Report

Retrieved on: 
Tuesday, November 15, 2022
Knowledge, The Oregon Trail 4th Edition, Growth, Medicine, Technology, Knowledge-centered support, Beckman Coulter, Biotechnology, POC, Roche, Sale, Histology, Cancer, IVD, Radiometer, Non-functional testing, Medical device, Pharmaceutical industry, Science, Cepheid variable

ARLINGTON, Va., Nov. 15, 2022 /PRNewswire-PRWeb/ -- Abbott is the #1 vendor in the United States in vitro diagnostics (IVD) market, according to United States Market for In Vitro Diagnostic (IVD) Tests, 4th Edition, a recent report from medical market researcher Kalorama Information. Roche is second and Danaher (which includes Radiometer, Beckman Coulter and Cepheid) was third.

Key Points: 
  • Roche is second and Danaher (which includes Radiometer, Beckman Coulter and Cepheid) was third.
  • These leading companies compete in a $54 billion market, according to the report, the 4th edition of Kalorama's dedicated analysis of the United States market.
  • Kalorama publishes reports on the in vitro diagnostics markets and has been for over two decades.
  • The U.S. IVD market is highly developed and, in some segments, dominated by a handful of leading market players.

Radiometer and Etiometry Announce Partnership to Enhance Neonatal Intensive Care Clinical Workflows and Patient Outcomes

Retrieved on: 
Thursday, June 30, 2022
Technology, Medical Devices, Hospitals, Clinical Trials, Software, Biotechnology, Health, Pharmaceutical, Data Management, Health, Critical care, Infant, Patient, Life, Intensive care unit, CEO, Caregiver, Adult, Carbon, Transcutaneous electrical nerve stimulation, Laboratory, Protocol, Ventilation, TCM, Radiometer, Partnership, Software, NICU, Quality of life, Solution, Blood, Hospital, Medicine, Medical imaging, Medical device

Etiometry , a leader in clinical decision-support software for critical care, and Radiometer , a leading medical device company specializing in acute care testing solutions, today announced a new collaboration to enhance the clinical workflows in Neonatal Intensive Care Units (NICU).

Key Points: 
  • Etiometry , a leader in clinical decision-support software for critical care, and Radiometer , a leading medical device company specializing in acute care testing solutions, today announced a new collaboration to enhance the clinical workflows in Neonatal Intensive Care Units (NICU).
  • Etiometry brings deep expertise in managing data analytics with our Clinical Decision Support platform that modernizes clinical workflow management and associated patient care activities through its customizable Clinical Management Application, said Shane Cooke, CEO of Etiometry.
  • Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data.
  • Through connected solutions, expert knowledge, and trusted partnership, we help health care professionals make diagnostic decisions to improve patient care.

Oman Blood Gas Analyzer, Poc Immunoassay Analyzer and Transcutaneous Monitor Market Outlook Report 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Health Technology, Health, Medical Devices, Radiometer, Industry, Quality, Technology, Health care, IAA, Nicu Popescu, Distribution, POC, GCC, BGA, Roche, TCM, Health, Intensive care unit, Abbott, Prevalence, Medical device, Growth

The "Oman Blood Gas Analyzer, Poc Immunoassay Analyzer and Transcutaneous Monitor Market Outlook - Remarkable Growth in the Distribution and Quality of Health Services in Oman Has Added to Previous Health Achievements and Stimulated the Growth in Future" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oman Blood Gas Analyzer, Poc Immunoassay Analyzer and Transcutaneous Monitor Market Outlook - Remarkable Growth in the Distribution and Quality of Health Services in Oman Has Added to Previous Health Achievements and Stimulated the Growth in Future" report has been added to ResearchAndMarkets.com's offering.
  • Oman Diagnostic Device Market (BGA, POC IAA and TCM) Overview and Size
    Oman Diagnostic Device market has presented remarkable growth in the distribution and quality of health services due to the high interest and planned objectives to improve the healthcare infrastructure in Oman.
  • Owing to the high interest in the new technology and faster technology BGA benchtop and Handheld devices slowly replaced the dependancy on the central devices.
  • Top players such as Radiometer, Roche and Abbott occupy the majority of the market.

Envista Announces Participation In Bank Of America Healthcare Conference

Retrieved on: 
Friday, May 7, 2021
Companies, Nobel Biocare, Danaher Corporation, Dental, KaVo Kerr, Health care, Radiometer

Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.

Key Points: 
  • Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.
  • Envista companies, including KaVo, Kerr, Nobel Biocare, and Ormco, partner with dental professionals to help them deliver the best possible patient care.\nEnvista separated from Danaher Corporation and became an independent company in 2019.
  • We brought with us the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus to meet the end-to-end needs of dental professionals worldwide.
  • Envista is now one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry.

Envista Announces Participation In JP Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021
Health, Nobel Biocare, Dental, Health care, KaVo Kerr, Radiometer

BREA, Calif., Jan. 5, 2021 /PRNewswire/ --Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the JP Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 PM ET.

Key Points: 
  • BREA, Calif., Jan. 5, 2021 /PRNewswire/ --Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the JP Morgan Healthcare Conference on Monday, January 11, 2021 at 4:30 PM ET.
  • Envista is a global family of more than 30 trusted dental brands, united by a shared purpose: to partner with professionals to improve lives.
  • Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services.
  • Envista companies, including KaVo, Kerr, Nobel Biocare, and Ormco, partner with dental professionals to help them deliver the best possible patient care.

Global Hematology Diagnostics Industry

Retrieved on: 
Monday, September 14, 2020
Branches of biology, Blood, Blood tests, Complete blood count, Hemoglobin, Platelet, Medical laboratory, Radiometer

Diagnostics by Geographic Region - France, Germany, Italy, UK,

Key Points: 
  • Diagnostics by Geographic Region - France, Germany, Italy, UK,
    Instruments and Consumables for the Years 2012, 2020 & 2027
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    by End-Use - Percentage Breakdown of Value Sales for Hospitals,
    Diagnostic labs and Other End-Uses for the Years 2012, 2020 &
    Instruments and Consumables for the Years 2012, 2020 & 2027
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    by End-Use - Percentage Breakdown of Value Sales for Hospitals,
    Diagnostic labs and Other End-Uses for the Years 2012, 2020 &
    Sales for Instruments and Consumables for the Years 2012, 2020 &
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    Instruments and Consumables for the Years 2012, 2020 & 2027
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    by End-Use - Percentage Breakdown of Value Sales for Hospitals,
    Diagnostic labs and Other End-Uses for the Years 2012, 2020 &
    Instruments and Consumables for the Years 2012, 2020 & 2027
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    End-Use - Percentage Breakdown of Value Sales for Hospitals,
    Diagnostic labs and Other End-Uses for the Years 2012, 2020 &
    Instruments and Consumables for the Years 2012, 2020 & 2027
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    by End-Use - Percentage Breakdown of Value Sales for Hospitals,
    Diagnostic labs and Other End-Uses for the Years 2012, 2020 &
    Sales for Instruments and Consumables for the Years 2012, 2020 &
    Diagnostics by Test Type - Blood count, Platelet function,
    Test Type - Blood count, Platelet function, Hemoglobin and
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    Sales for Instruments and Consumables for the Years 2012, 2020 &
    Hematology Diagnostics by Test Type - Blood count, Platelet
    Diagnostics by Test Type - Blood count, Platelet function,
    Hematology Diagnostics by End-Use - Hospitals, Diagnostic labs
    Diagnostics by End-Use - Hospitals, Diagnostic labs and Other
    Hematology Diagnostics by Geographic Region - Australia, India,
    ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition

Retrieved on: 
Thursday, April 30, 2020
Companies, Sartorius AG, General Electric, Danaher Corporation, Radiometer

The combined revenue of the businesses, which were part of Danaher's Life Sciences segment, was approximately $170 million in 2019.

Key Points: 
  • The combined revenue of the businesses, which were part of Danaher's Life Sciences segment, was approximately $170 million in 2019.
  • Danaher sold these businesses in order to obtain regulatory approval for its acquisition of the GE Biopharma business, now called Cytiva.
  • The closing of the Sartorius AG agreement was conditioned upon Danaher closing its acquisition of Cytiva, which was completed on March 31, 2020.
  • Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets.

Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva

Retrieved on: 
Tuesday, March 31, 2020
Danaher Corporation, Companies, DHR, Radiometer

WASHINGTON, March 31, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's (NYSE: GE) Life Sciences division.

Key Points: 
  • WASHINGTON, March 31, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's (NYSE: GE) Life Sciences division.
  • As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment.
  • Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world.
  • Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets.